Leading international law firm SJ Berwin has advised Watson Pharmaceuticals, Inc on the acquisition of Belgium-based development company Uteron Pharma for $150 million in cash up front, and up to $155 million in potential future milestone payments.

Listed on the New York Stock Exchange, Watson is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The acquisition of Uteron expands Watson's pipeline of female healthcare products.

Ed Harris led the SJ Berwin team, which pooled the resources of the firm’s London and Brussels offices and included London commercial partner Andrew Shindler, corporate associates Carl Dickinson and Jacob Traff and Brussels corporate counsel Olivier Armand and corporate associate Janine de Keersmaecker.

http://www.sjberwin.com/newsdetails.aspx?hd=news&pid=3249&ctid=0&mid=1&…